| Overview |
| bs-7862R-Cy5 |
| FAM3C Polyclonal Antibody, Cy5 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Rat |
| Mouse, Dog, Cow, Pig, Horse, Chicken |
| Specifications |
| Cy5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human FAM3C |
| 151-227/227 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 10447 |
| Cytoplasm, Secreted |
| Fam3c; FAM3C_HUMAN; family with sequence similarity 3, member C; GS3786;ILEI; Interleukin-like EMT inducer; Predicted osteoblast protein; Protein FAM3C. |
| ILEI is a 227 amino acid, ubiquitously expressed protein containing an amino-terminal signal peptide. Elevated levels of ILEI translation are observed in oncogenic, Ras-transformed mammary epithelial cells and epithelial to mesenchymal transition (Emt) as well as tumor growth and metastasis. Also, overexpression of ILEI results in loss of ZO-1, a protein involved in tight junctions, and expression of cytoplasmic E-cadherin, which has been shown to influence loss of polarity and invasiveness. Due to this evidence, it is suspected that ILEI cooperates with oncogenic Ras to cause TGF-independent Emt and its overexpression is correlated with the invasion, metastasis and survival in a variety of cancers. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz